Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Simon N. Pimstone net worth and biography

Simon Pimstone Biography and Net Worth

Director of Xenon Pharmaceuticals

Dr. Simon Pimstone received his MD from the University of Cape Town. He is an Internal Medicine specialist (FRCPC, UBC, 2001) with an interest in cardiovascular disease. Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at UBC and obtained his PhD through the University of Amsterdam in cardiovascular genetics in 1998.

Dr. Pimstone serves as consultant physician at the UBC Medical and Cardiology Clinic at UBC Hospital in Vancouver. He is a founder and co-PI of the Study to Avoid cardioVascular events in BC (SAVE BC), a provincial program screening families with very premature atherosclerotic cardiovascular disease. After seeing two close friends suffer major myocardial infarctions under forty years of age, he was moved to establish a screening platform in BC to ensure we do what we can to identify high risk individuals as early as possible. SAVE BC was the solution to this challenge.

Dr. Pimstone is also a founder, Director, and President and Chief Executive Officer at Xenon Pharmaceuticals Inc., one of Canada’s leading publicly traded biotechnology companies (Nasdaq: XENE). He has also held positions on a number of life sciences and biotechnology boards.

What is Simon N. Pimstone's net worth?: The estimated net worth of Simon N. Pimstone is at least $231,780.00 as of May 31st, 2023. Dr. Pimstone owns 6,000 shares of Xenon Pharmaceuticals stock worth more than $231,780 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Pimstone may own. Learn More about Simon N. Pimstone's net worth.
How do I contact Simon N. Pimstone?: The corporate mailing address for Dr. Pimstone and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Simon N. Pimstone's contact information.
Has Simon N. Pimstone been buying or selling shares of Xenon Pharmaceuticals?: Simon N. Pimstone has not been actively trading shares of Xenon Pharmaceuticals during the past quarter. Most recently, Simon N. Pimstone sold 62,526 shares of the business's stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $38.70, for a transaction totalling $2,419,756.20. Following the completion of the sale, the director now directly owns 6,000 shares of the company's stock, valued at $232,200. Learn More on Simon N. Pimstone's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 43,737 shares worth more than $1,903,860.53. The most recent insider tranaction occured on December, 18th when CFO Sherry Aulin sold 18,709 shares worth more than $770,997.89. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 12/18/2024.

Simon N. Pimstone Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2023	Sell	62,526	$38.70	$2,419,756.20	6,000
3/7/2023	Sell	19,232	$36.98	$711,199.36	34,002
8/15/2022	Sell	33,942	$37.76	$1,281,649.92	58,058
8/12/2022	Sell	91,135	$38.28	$3,488,647.80	92,000
3/7/2022	Sell	31,086	$30.50	$948,123.00
3/4/2022	Sell	9,325	$30.61	$285,438.25
11/15/2021	Sell	17,557	$31.33	$550,060.81
6/1/2020	Sell	3,000	$14.43	$43,290.00	258,186
5/29/2020	Sell	5,000	$13.99	$69,950.00	258,186
9/20/2019	Sell	10,395	$9.51	$98,856.45	258,122
8/10/2017	Buy	6,000	$2.90	$17,400.00	217,847

Simon N. Pimstone Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.63

$38.00

$39.46

50 Day Range

MA: $41.85

$38.31

$45.74

2 Week Range

Now: $38.63

$35.53

$50.99

Volume

1,054,236 shs

Average Volume

391,447 shs

Market Capitalization

$2.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Most People Are Dead Wrong.

From Brownstone Research | Ad